Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine

Pediatric Blood and Cancer

Volumn 50, Issue 1, 2008, Pages 72-79

  Dhall, Girish ^a   Finlay, Jonathan L ^a   Dunkel, Ira J ^b   Ettinger, Lawrence J ^c   Kellie, Stewart J ^d   Allen, Jeffrey C ^e   Egeler, R Maarten ^f   Arceci, Robert J ^g  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

2 CDA; Central nervous system; Cladribine; Langerhans cell histiocytosis

Indexed keywords

ANTICONVULSIVE AGENT; CLADRIBINE; CYCLOSPORIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BONE MARROW SUPPRESSION; BRAIN ATROPHY; BRAIN RADIATION; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHOROID PLEXUS; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES INSIPIDUS; DISEASE COURSE; DISEASE FREE INTERVAL; DRUG ACTIVITY; DRUG TOLERABILITY; DURA MATER; FEMALE; FOLLOW UP; HISTIOCYTOSIS X; HUMAN; HYPOPITUITARISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMAGE ENHANCEMENT; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; CLADRIBINE; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 36849075658     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21225     Document Type: Article

References (27)

1. Chu T, D'Angio GJ, Favara B, et al. Histiocytosis syndromes in children: By the Writing Group of the Histiocyte Society. Lancet 1987;1:208-209.
2. Arceci RJ, Longley BJ, Emauel PD. Atypical cellular disorders. Hematology (Am Soc Hematol Educ Program) 2002: 297-314.
3. Arico M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:247-258.
4. Grois NG, Favara BE, Mostbeck GH, et al. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:287-306.
5. Hund E, Steiner H, Jansen O, et al. Treatment of cerebral Langerhans cell histiocytosis. J Neurol Sci 1999;171:145-152.
6. Saven A, Figueroa ML, Piro LD. 2-chlorodeoxyadenosine to treat refractory histiocytosis. N Engl J Med 1993;329:734-735.
7. Stine KC, Saylors RL, Williams LL, et al. 2-chlorodeoxyadenosine for the treatment of refractory or recurrent Langerhans cell histiocytosis in pediatric patients. Med Pediatr Oncol 1997;29:288-292.
8. Rodriguez-Galindo C, Kelly P, Jeng M, et al. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hematol 2002;69:179-184.
9. Pardanani A, Phyliky RL, Li C, et al. 2-chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003;78:301-306.
10. Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:81-84.
11. Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Kin Padiatr 2000;212:139-144.
12. Whitsett SF, Kneppers K, Coppes M, et al. Neuropsychologic deficits in children with Langerhans cell Histiocytosis. Med Pediatr Oncol 1999;33:486-492.
13. Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:221-246.
14. Grois N, Broadbent V, Pavara BE, et al. Report of the Histiocyte Society on "Central Nervous System Disease in Langerhans Cell Histiocytosis". Med Pediatr Oncol 1997; 29: 73-78.
15. Grois N, Prayer D, Prosch H, et al. Neuropathology of CNS disease in Langerhans cell Histiocytosis. Brain 2005;128:829-838.
16. Grois N, Flucher-Wolfram B, Heitger A, et al. Diabetes insipidus in Langerhans cell histiocytosis: Results from the DAL-HX 83 study. Med Pediatr Oncol 1995;4:248-256; Report of the Histiocyte Society Workshop on "Central Nervous System Disease in Langerhans Cell Histiocytosis." Med Pediatr Oncol 1997;29:73-78.
17. Donadieu J, Rolon M, Thomas C, et al. Endocrine involvement in pediatric-onset Langerhans cell histiocytosis: A population based study. J Pediatr 2004;144:344-350.
18. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: A case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003;25:575-577.
19. Donadieu J, Rolon M, Thomas C, et al. Endocrine involvement in pediatric-onset Langerhans cell histiocytosis: A population based study. J Pediatr 2004;144:344-350.
20. Rosenzweig KE, Arceci RJ, Tarbell NJ. Diabetes inspidus secondary to langerhans cell histiocytosis: Is radiation therapy indicated? Med Pediatr Oncol 1997;29:36-40.
21. Nanduri V, Lillywhite L, Chapman C, et al. Cognitive outcome of long-term survivors of multisystem Langerhans cell histiocytosis: A single-institution, cross-sectional study. J Clin Oncol 2003;21:2961-2967.
22. Mittheisz E, Seidl R, Prayer D, et al. Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2007;48:50-56.
23. Haupt R, Nanduri V, Grazia M, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society-Late effects study group. Pediatr Blood Cancer 2004;42:438-444.
24. Barbieri D, Abbracchio MP, Salvioli S, et al. Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 1998;32:493-504.
25. Weitzman S, Wayne AS, Arceci R, et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the Histiocyte Society and review of literature. Med Pediatr Oncol 1999;33:476-481.
26. Watts J, Files B. Langerhans cell histiocytosis: Central nervous system involvement treated successfully with 2-Chlorodeoxyadenosine. Pediatr Hemat Oncol 2001;18:199-244.
27. Buchler T, Cervinek L, Belohlavek O, et al. Langerhans cell Histiocytosis with central nervous system involvement: Follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer 2005;44:286-288.